Other

China Petroleum Chemical Corporation

Fmr Corp.

Dalian Research Institute of Petroleum and Petrochemicals, Sinopec Corp.

Dalian Fusheng Natural Medicine Development Co., Ltd.

Fu, Li

Li Fu

Kaiqian Wang

Shuo Wang

Zhengxian Liu

Hongyu Fan

Qiang Fu

Qi Lu

Xin Gai

Min Hui

Yang Liu

Mingming Lu

Hongying Qu

Xiaojing Yu

Hailing Wang

Yu Zhang

Nayan Patel

Kevin Handy

Jianfeng Zhang

Fan Li

Renwu Jiang

Shuhua Liu

Jiaohe Guo

Hanrong Yao

Hong Liu

Seong Tae Cho

Wanzhe Cui

Methods and apparatuses are described for caching login sessions to access a software testing environment. A server identifies a test case for execution against an application in the software testing environment, the test case comprising one or more test steps. The server retrieves test data based upon the identified test case and generates a session key using the test data. The server requests an active session from a login session cache using the session key. When an active session exists in the login session cache, the server receives, from the login session cache, session data corresponding to the active session, establishes a connection to the application in the software testing environment using the session data and without first authenticating to the software testing environment, and executes one or more test steps of the test case against the application in the software testing environment using the test data.

Caching login sessions to access a software testing environment

The present invention discloses a composition of phillyrin and phillygeninin in the preparation of drugs for alleviating or/and treating viral diseases. Experiments prove that the composition of phillyrin and phillygeninin has significant treatment effects on viral influenza and pneumonia, as well as on respiratory syncytial viruses, enteroviruses, herpes zoster simplex viruses, Coxsackie viruses, and the like. This composition is characterized by quick action and less toxic and side effects, and thus is an antiviral drug and health product with safety, high efficiency, stability and simple preparation process, and is suitable for industrial production and easy to promote. The present invention provides a drug, health product and raw material for preventing and treating various viral diseases.

Application of a phillyrin/phillygeninin composition in preparing a medicine or health care product for alleviating or/and treating viral diseases, and medicine or health care product for treating viral diseases

Modified asphalt particles contain asphalt and a modifier. The modifier comprises poly-sulfur and free sulfur. The sulfur element accounts for 10-40 weight percent of the total amount of the modified asphalt particles, and the poly-sulfur accounts for 30-70 weight percent of the total amount of the sulfur element. The total particle size of the modified asphalt particle is smaller than or equal to 150 &#x3bc;m. The modified asphalt particles have an excellent high temperature performance, and can be used for preparing drilling fluids. Water-in-oil based drilling fluid obtained from the modified asphalt particles has low plastic viscosity, high dynamic shear force, high dynamic plastic ratio, and high emulsion-breaking voltage, and improves the high temperature resistance and cutting carrying capability of a system.

Modified asphalt particles and preparation method and use thereof

The invention discloses new application of a ginseng extract, ginsenoside and a ginsenoside derivative in the preparation of a medicine for treating HCMV infection related diseases. The related diseases comprise HCMV infection caused in the process of treating cardiovascular and cerebrovascular diseases, organ transplantation, perinatal periods, tumors, burn, AIDS and other diseases of patients. Tests prove that the ginseng extract, the ginsenoside and the ginsenoside derivative have a remarkable curative effect, quick response and a small toxic or side effect during treatment of HCMV infected diseases, are a medicine or a health product for treating the HCMV infection, which is safe, efficient and stable and has a simple preparation process, and are suitable for industrial production and easy to popularize. In the invention, a new medicine source is provided for the treatment of the HCMV infection.

Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders

The present invention provides a novel phillygenin glucuronic acid derivative shown as a general formula (I). wherein, R=H, R=CH, R=CHor R=CH, R=CH,R=H or R-R=&#x2014;CH&#x2014;, R=CH; n=1-30. The present invention further relates to a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, as well as application of the compound in the present invention in antiviral diseases.

Phillygenin glucuronic acid derivative as well as preparation method and application thereof

The present invention relates to a chemical synthesis method for phillyrin. The method of the present invention comprises: first dissolving a glycosyl receptor phillygenin and a glycosyl donor in an organic solvent for glycosylation to obtain tetraacyl phillyrin; then dissolving the tetraacyl phillyrin in a second organic solvent, and adding sodium methoxide for deacylation, adding an acidic pH regulator to regulate the pH value of the reaction mixture to neutral; and finally carrying out purification treatment to obtain phillyrin. The advantages and practical values of the chemical synthesis method for phillyrin of the present invention lie in: the raw material is easy to get, the catalysts used for glycosylation are cheap and easy to get, the production cost is greatly reduced, and it can be used for industrial production.

Chemical synthesis method of phillyrin

The present invention discloses a new application of a composition of phillyrin and phillygeninin in the preparation of drugs for alleviating or/and treating viral diseases. Experiments prove that the composition of phillyrin and phillygeninin has significant treatment effects on viral influenza and pneumonia, as well as on respiratory syncytial viruses, enteroviruses, herpes zoster simplex viruses, Coxsackie viruses, and the like. This composition is characterized by quick action and less toxic and side effects, and thus is an antiviral drug and health product with safety, high efficiency, stability and simple preparation process, and is suitable for industrial production and easy to promote. The present invention provides a new drug, health product and raw material for preventing and treating various viral diseases.

The present invention discloses an application of ginsenoside Rg3 in preparing a medicine or product for preventing and treating dementia, and a preparation method thereof, which belong to the fields of medicines and health care products, and its products comprise a topical preparation, oral preparation and injection of the ginsenoside Rg3; and the Rg3 medicine or formulating prepared Rg3 compound medicine is prepared by using a solubilizer, a transdermal agent, a reagent promoting the absorption by penetrating a blood-brain barrier and an extractive, achieving the effect that the medicine penetrates the blood-brain barrier, and is used for preventing and treating dementia.

Application of ginsenoside RG3 in preparing medicine for preventing and/or treating dementia, and medicine for treating dementia

The present invention provides 20(R)-ginsenoside Rg3 polyacylated derivatives of the formula (I) and preparation method and anti-tumor application thereof: wherein, R&#x2550;CH(CH)nCO, n=0&#x2dc;5.

20(R)-ginsenoside Rg3 polyacylated derivatives, preparation and application thereof

The present invention provides a pharmaceutical compound of phillygenin ibuprofen ester as represented by formula (I), preparation method thereof, and applications thereof in anti-virus, antipyresis, anti-inflammation, analgesia and the like: 

Phillygenin ibuprofen ester, preparation method therefor, and application thereof

The present invention provides a forsythiaside sulfate derivatives as represented by the following formula, the preparation method and antiviral application thereof: 

Forsythiaside sulfate and derivatives thereof, preparation method and application thereof

A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5&#x2dc;10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1&#x2dc;30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40&#x2dc;100&#xb0; C., the ratio of these two is 1:1&#x2dc;300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1&#x2dc;2 mg/ml of 20 (R) of the ginsenoside Rg3, the preparation: add 0.1&#x2dc;5% of ginsenoside solution to 20&#x2dc;65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60&#x2dc;100&#xb0; C., main material to adjuvant B=1:100&#x2dc;400, add water after the solvent is recycled under reduced pressure. The above 20 (R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilization can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving.

Aqueous solution of 20(R)-ginsenoside RG3 pharmaceutical composition and process thereof

A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5&#x2dc;10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1&#x2dc;30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40&#x2dc;100&#xb0; C., the ratio of these two is 1:1&#x2dc;300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1&#x2dc;2 mg/ml of 20(R) of the ginsenoside Rg3, the preparation: add 0.1&#x2dc;5% of ginsenoside solution to 20&#x2dc;65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60&#x2dc;100&#xb0; C., main material to adjuvant B=1:100&#x2dc;400, add water after the solvent is recycled under reduced pressure. The above 20(R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilizaton can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving.

Growing community of inventors

Dalian, China

Li Fu